search
Back to results

Danish National Randomized Study on Early Aortic Valve Replacement in Patients With Asymptomatic Severe Aortic Stenosis (DANAVR)

Primary Purpose

Aortic Valve Stenosis, Diastolic Dysfunction

Status
Recruiting
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Aortic valve replacement
Sponsored by
Odense University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Aortic Valve Stenosis

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 1. Severe AS defined as

    1. aortic valve area (AVA) ≤1 cm2, AND
    2. Transvalvular maximum velocity (Vmax) ≥3.5 m/s AND
    3. AS severity evaluated severe by a heart valve team conference. In cases where severity is not unambiguous an integrative approach will be utilized combining echocardiographic markers of valve severity and LV function, and if necessary aortic valve calcification estimated by non-contrast CT.

      2. Considered to be asymptomatic (estimated by a consultant in cardiology) 3. Considered to be candidate for AVR (transcatheter AVR/surgical AVR) 4. Sign of increased LV filling pressures18 or reduced longitudinal LV systolic function

    1. Left atrial volume index (LAVi) > 34 ml/m2; OR
    2. ratio of early diastolic peak mitral inflow velocity (E) to early mitral annulus diastolic velocity (e') ratio E/e'avg>13; OR
    3. Threefold elevation in NT-proBNP compared to the upper expected age and gender value. OR
    4. GLS>-15 5. Age ≥18 years 6. Signed informed consent

Exclusion Criteria:

  1. LVEF<50%
  2. Very severe AS defined as Vmax>5 m/s.
  3. Concomitant severe valvular disease other than AS
  4. Previous valvular surgery
  5. Estimated glomerular filtration rate<30 ml/min/m2
  6. Dementia
  7. Women of childbearing potential
  8. Inability to provide informed consent
  9. Age>85 years.
  10. Supravalvular or subvalvular AS

Sites / Locations

  • Odense University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

No Intervention

Arm Label

Early intervention

Watchfull waiting

Arm Description

Patients will undergo aortic valve replacement immediately

Patients will be followed and treated as recommended by guidelines.

Outcomes

Primary Outcome Measures

all-cause mortality
All-cause mortality assessed by Danish patient records

Secondary Outcome Measures

Combined endpoint
All-cause mortality + hospitalization due to heart failure and stroke
all-cause mortality in patients with low-gradient AS
All-cause mortality in patients with meangradient <40 mmHg
Combined endpoint in low-gradient AS
All-cause mortality + hospitalization to heart failure and stroke when MG<40 mmHg

Full Information

First Posted
May 31, 2019
Last Updated
September 9, 2020
Sponsor
Odense University Hospital
Collaborators
Rigshospitalet, Denmark, Aarhus University Hospital, Aalborg University Hospital, Zealand University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03972644
Brief Title
Danish National Randomized Study on Early Aortic Valve Replacement in Patients With Asymptomatic Severe Aortic Stenosis
Acronym
DANAVR
Official Title
Danish National Randomized Study on Early Aortic Valve Replacement in Patients With Asymptomatic Severe Aortic Stenosis
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Recruiting
Study Start Date
January 1, 2020 (Actual)
Primary Completion Date
September 1, 2029 (Anticipated)
Study Completion Date
September 1, 2029 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Odense University Hospital
Collaborators
Rigshospitalet, Denmark, Aarhus University Hospital, Aalborg University Hospital, Zealand University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to examine the impact of early surgery in patients with asymptomatic severe aortic valve stenosis with signs of subclinical LV dysfunction despite preserved LVEF, with a watchfull waiting approach.
Detailed Description
Since the seminal paper by Ross and Braunwald, the development of symptoms has been regarded as one of the most important precursors of a poor outcome in aortic stenosis (AS), and is today half a century later, still the leading reason for referral for aortic valve replacement (AVR). The development of symptoms is however often preceded by structural changes in the left ventricle (LV).These changes including concentric remodeling and LV hypertrophy have been regarded as compensative measures to adapt the LV to increased ventricular afterload. Although LV hypertrophy may preserve wall-stress in the normal range and increase contractility allowing the preservation of stroke volume, this occurs at the expense of increased filling pressures. Diastolic dysfunction with increased filling pressure lead to left atrial (LA) dilatation and significantly contributes to the development of symptoms. Despite successful surgery, AS patients have increased long-term mortality and morbidity compared to the general population, and the outcome is largely determined by the degree of preoperative structural LV and LA alterations. This has led to the theory that AVR prior to the development of symptoms could improve outcome, a view supported by prospective and retrospective studies.These studies were however small, with some important limitations. In addition, there has been a concern that operative risk and prosthetic valve related long-term morbidity and mortality does not justify surgery on every asymptomatic patient with severe AS. Numerous studies have suggested that markers of LV structure and function, particularly LA volume index,E/e' and brain natriuretic peptides (BNP) all reflecting LV filling pressures may identify patients with benefit of early AVR. Accordingly, the most recent European guideline for management of valvular disease has implemented BNP as a class IIa recommendation for AVR in asymptomatic AS patients,although no randomized studies have demonstrated that early surgery based on these markers improve prognosis. The purpose of this study is thus to evaluate if early AVR in patients with signs of elevated LV filling pressuresmay improve long-term outcome in patients with asymptomatic severe AS, compared to conventional symptom-guided surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Aortic Valve Stenosis, Diastolic Dysfunction

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1700 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Early intervention
Arm Type
Active Comparator
Arm Description
Patients will undergo aortic valve replacement immediately
Arm Title
Watchfull waiting
Arm Type
No Intervention
Arm Description
Patients will be followed and treated as recommended by guidelines.
Intervention Type
Procedure
Intervention Name(s)
Aortic valve replacement
Intervention Description
Open heart surgery or transcatheter surgery
Primary Outcome Measure Information:
Title
all-cause mortality
Description
All-cause mortality assessed by Danish patient records
Time Frame
After 379 events (approx 5 years)
Secondary Outcome Measure Information:
Title
Combined endpoint
Description
All-cause mortality + hospitalization due to heart failure and stroke
Time Frame
After 379 events (approx 5 years)
Title
all-cause mortality in patients with low-gradient AS
Description
All-cause mortality in patients with meangradient <40 mmHg
Time Frame
After 379 events (approx 5 years)
Title
Combined endpoint in low-gradient AS
Description
All-cause mortality + hospitalization to heart failure and stroke when MG<40 mmHg
Time Frame
After 379 events (approx 5 years)
Other Pre-specified Outcome Measures:
Title
Pericardiocentesis
Description
Need of pericariocentesis
Time Frame
5 years
Title
sternal infection
Description
hospitalization due to sternal infection
Time Frame
5 years
Title
Persistent renal failure
Description
complete loss of renal function exceeding 4 weeks.
Time Frame
5 years
Title
endocarditis
Description
hospitalization due to endocarditis
Time Frame
5-years
Title
major bleeding
Description
intracerebral bleeding or bleeding resulting in substantial hemodynamic compromise requiring treatment instability
Time Frame
5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 1. Severe AS defined as aortic valve area (AVA) ≤1 cm2, AND Transvalvular maximum velocity (Vmax) ≥3.5 m/s AND AS severity evaluated severe by a heart valve team conference. In cases where severity is not unambiguous an integrative approach will be utilized combining echocardiographic markers of valve severity and LV function, and if necessary aortic valve calcification estimated by non-contrast CT. 2. Considered to be asymptomatic (estimated by a consultant in cardiology) 3. Considered to be candidate for AVR (transcatheter AVR/surgical AVR) 4. Sign of increased LV filling pressures18 or reduced longitudinal LV systolic function Left atrial volume index (LAVi) > 34 ml/m2; OR ratio of early diastolic peak mitral inflow velocity (E) to early mitral annulus diastolic velocity (e') ratio E/e'avg>13; OR Threefold elevation in NT-proBNP compared to the upper expected age and gender value. OR GLS>-15 5. Age ≥18 years 6. Signed informed consent Exclusion Criteria: LVEF<50% Very severe AS defined as Vmax>5 m/s. Concomitant severe valvular disease other than AS Previous valvular surgery Estimated glomerular filtration rate<30 ml/min/m2 Dementia Women of childbearing potential Inability to provide informed consent Age>85 years. Supravalvular or subvalvular AS
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jordi S Dahl, MD, PhD
Phone
+4523823016
Email
jordi.dahl@rsyd.dk
First Name & Middle Initial & Last Name or Official Title & Degree
Jacob E Møller, MD, PhD
Email
jem@dadlnet.dk
Facility Information:
Facility Name
Odense University Hospital
City
Odense
State/Province
Fyn
ZIP/Postal Code
5000
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jordi S Dahl, MD, Ph.D
Phone
23823016
Email
jordi.dahl@rsyd.dk

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Danish National Randomized Study on Early Aortic Valve Replacement in Patients With Asymptomatic Severe Aortic Stenosis

We'll reach out to this number within 24 hrs